Testing two drugs together for NF2 tumors that are growing
Official title: Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study is checking whether two drugs, given together, are safe for people whose NF2 tumors are growing.
Read our full plain-language summary
What the trial team says
This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.
Key facts
- Registry number
- NCT07708285
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, Meningioma
Where it is running
This trial lists 5 sites.
-
Beijing Municipality
- Xuanwu Hospital, Capital Medical University (Beijing)
- Beijing Tiantan Hospital, Capital Medical University (Beijing)
- Chinese PLA General Hospital (Beijing)
-
Jilin
- The First Hospital of Jilin University (Changchun)
-
Shanghai Municipality
- Shanghai General Hospital (Shanghai)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.